Ariad Investor Says Drug Side Effects Led To Stock Drop

Law360, Los Angeles (October 17, 2013, 4:08 PM EDT) -- An investor hit Ariad Pharmaceuticals Inc. with a putative class action in Massachusetts federal court on Thursday, alleging the oncology company made false statements about its leukemia drug Iclusig then disclosed the dangerous side effects later, causing Ariad’s stock to plummet nearly 66 percent.

The suit comes a week after Iclusig drew the scrutiny of the U.S. Food and Drug Administration due to growing reports of blood clots among patients taking Iclusig and due to Ariad's announcement of plans to stop admitting new patients into clinical...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Burch v. Ariad Pharmaceuticals, Inc. et al


Case Number

1:13-cv-12626

Court

Massachusetts

Nature of Suit

Securities/Commodities

Judge

William G. Young

Date Filed

October 17, 2013

Law Firms

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.